A safety and pharmacokinetic study of a mixed-backbone oligonucleotide (GEM231) targeting the type I protein kinase a by two-hour infusions in patients with refractory solid tumors

Clinical Cancer Research

Volumn 6, Issue 4, 2000, Pages 1259-1266

  Chen, Helen X ^a   Marshall, John L ^a   Ness, Elizabeth ^a   Martin, R Russell ^b   Dvorchik, Barry ^b   Rizvi, Naiyer ^a   Marquis, Judith ^b   McKinlay, Margo ^b   Dahut, William ^a   Hawkins, Michael J ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b HYBRIDON INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; GENE EXPRESSION MODULATOR 231; OLIGONUCLEOTIDE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; CONCENTRATION RESPONSE; DRUG HALF LIFE; DRUG SAFETY; FEMALE; GENE TARGETING; HUMAN; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; RECEPTOR DOWN REGULATION; SOLID TUMOR; THROMBOCYTE COUNT;

AGED; ALANINE TRANSAMINASE; AREA UNDER CURVE; BASE SEQUENCE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, RENAL CELL; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FATIGUE; FEMALE; FEVER; HUMANS; INFUSIONS, INTRAVENOUS; KIDNEY NEOPLASMS; LUNG NEOPLASMS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PARTIAL THROMBOPLASTIN TIME; SARCOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 20244380289     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Webb, A., Cunningham, D., Cotter, F., Clarke, P. A., di Stefano, F., Ross, P., Corbo, M., and Dziewanowska, Z. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma. Lancet, 349: 1137-1141, 1997.
2. Sikic, B. I., Yuen, A. R., Halsey, J., Fisher, G. A., Pribble, J. P., Smith, R. M., and Dorr, A. A Phase I trial of an antisense oligonucleotide targeted to protein kinase C-α (ISIS 3521) delivered by 21-day continuous intravenous infusion. Proc. Am. Soc. Clin. Oncol., 33rd Annual Meeting, Abstract 791, 1997.
3. Holmound, J., Nemunaitis, J., Schiller, J., Dorr, A., and Kisner, D. Phase I trial of c-raf antisense oligonucleotide ISIS 5132 (CGP 69846A) by 21-day continuous intravenous infusion in patients with advanced cancer. Proc. Am. Soc. Clin. Oncol., 34th Annual Meeting, Abstract 811, 1998.
4. Shaw, D. R., Rustagi, P. K., Kandimalla, E. R., Manning, A. N., Jiang, Z., and Agrawal, S. Effects of synthetic oligonucieotides on human complement and coagulation. Biochem. Pharmacol., 53: 1123-1132, 1997.
5. Nemunaitis, J., Von Hoff, D. D., Holmlund, J., Dorr, A., and Eckhardt, S. G. Phase I pharmacokinetic (PK) trial of a protein kinase C-α antisense oligonucleotide, ISIS 3521 (CGP 64128A), administered thrice weekly. Proc. Am. Soc. Clin. Oncol., 34th Annual Meeting, Abstract 812, 1998.
6. Phillips, J. A., Craig, S. J., Bayley, D., Christian, R. A., Geary, R., and Nicklin, P. L. Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem. Pharmacol., 54: 657-668, 1997.
7. Agrawal, S., and Zhao, Q. Mixed backbone oligonucieotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev., 8: 135-139, 1998.
8. Agrawal, S., Jiang, Z., Zhao, Q., Shaw, D., Cai, Q., Roskey, A., Channavajjala, L., Saxinger, C., and Zhang, R. Mixed-backbone oligonucieotides as second generation antisense oligonucieotides: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA, 94: 2620-2625, 1997.
9. Beebe, S., and Corbin, J. The enzyme: control by phosphorylation part A. In: P. Boyer and E. Kerbes (eds.), Academic Press, Vol. 17, pp. 43-111. New York: Academic Press, 1986.
10. Cho-Chung, Y. S., and Clair, T. The regulatory subunit of cAMP-dependent protein kinase as a target for chemotherapy of cancer and other cellular dysfunctional-related diseases. Pharmacol Ther., 60: 265-288, 1993.
11. Rohlff, C., Clair, T., and Cho-Chung, Y. S. 8-Cl-cAMP induces truncation and down-regulation of the RIα subunit and up-regulation of the RIIβ subunit of cAMP-dependent protein kinase leading to type II holoenzyme-dependent growth inhibition and differentiation of HL-60 leukemia cells. J. Biol. Chem., 268: 5774-5782, 1993.
12. Tortora, G., Clair, T., and Cho-Chung, Y. S. An antisense oligodeoxynucleotide targeted against the type IIβ regulatory subunit mRNA of protein kinase inhibits cAMP-induced differentiation in HL-60 leukemia cells without affecting phorbol ester effects. Proc. Natl. Acad. Sci. USA, 87: 705-708, 1990.
13. Tortora, G., Pepe, S., Bianco, C., Baldassarre, G., Budillon, A., Clair, T., Cho-Chung, Y. S., Bianco, A. R., and Ciardiello, F. The RIα subunit of protein kinase A controls serum dependency and entry into cell cycle of human mammary epithelial cells. Oncogene, 9: 3233-3240, 1994.
14. Ciardiello, F., Pepe, S., Bianco, C., Baldassarre, G., Ruggiero, A., Selvam, M. P., Bianco, A. R., and Tortora, G. Down-regulation of RIα subunit of cAMP-dependent protein kinase induces growth inhibition of human mammary epithelial cells transformed by c-Ha-ras and c-erbB-2 proto-oncogenes. Int. J. Cancer, 53: 438-443, 1993.
15. Ciardiello, F., Tortora, G., Kim, N., Clair, T., Ally, S., Salomon, D. S., and Cho-Chung, Y. S. 8-Chloro-cAMP inhibits transforming growth factor a transformation of mammary epithelial cells by restoration of the normal mRNA patterns for cAMP-dependent protein kinase regulatory subunit isoforms which show disruption upon transformation. J. Biol. Chem., 265: 1016-1020, 1990.
16. Tortora, G., Damiano, V., Bianco, C., Baldassarre, G., Bianco, A. R., Lanfrancone, L., Pelicci, P. G., and Ciardiello, F. The RIα subunit of protein kinase A (PKA) binds to Grb2 and allows PKA interaction with the activated EGF-receptor. Oncogene, 14: 923-928, 1997.
17. Miller, W. R., Watson, D. M., Jack, W., Chetty, U., and Elton, R. A. Tumour cyclic AMP binding proteins: an independent prognostic factor for disease recurrence and survival in breast cancer. Breast Cancer Res. Treat., 26: 89-94, 1993.
18. Simpson, B., Ramage, A., Hulme, M., Burns, D., Katsaros, D., Langdon, S., and Miller, W. Cyclic adenosine 3′,5′-monophosphage-binding proteins in human ovarian cancer: correlation with clinicopathological features. Clin. Cancer Res., 2: 201-206, 1996.
19. McDaid, H. M., Cairns, M. T., Atkinson, R. J., McAleer, S., Harkin, D. P., Gilmore, P., and Johnston, P. G. Increased expression of the RIα subunit of the cAMP-dependent protein kinase A is associated with advanced stage ovarian cancer. Br. J. Cancer, 79: 933-939, 1999.
20. Ally, S., Clair, T., Katsaros, D., Tortora, G., Yokozaki, H., Finch, R. A., Avery, T. L., and Cho-Chung, Y. S. Inhibition of growth and modulation of gene expression in human lung carcinoma in athymic mice by site-selective 8-Cl-cyclic adenosine monophosphate. Cancer Res., 49: 5650-5655, 1989.
21. Ramage, A. D., Langdon, S. P., Ritchie, A. A., Burns, D. J., and Miller, W. R. Growth inhibition by 8-chloro cyclic AMP of human HT29 colorectal and ZR-75-1 breast carcinoma xenografts is associated with selective modulation of protein kinase A isoenzymes. Eur. J. Cancer, 31A: 969-973, 1995.
22. Tortora, G., Yokozaki, H., Pepe, S., Clair, T., and Cho-Chung, Y. S. Differentiation of HL-60 leukemia by type I regulatory subunit antisense oligodeoxynucleotide of cAMP-dependent protein kinase. Proc. Natl. Acad. Sci. USA, 88: 2011-2015, 1991.
23. Yokozaki, H., Budillon, A., Tortora, G., Meissner, S., Beaucage, S. L., Miki, K., and Cho-Chung, Y. S. An antisense oligodeoxynucleotide that depletes RIα subunit of cyclic AMP-dependent protein kinase induces growth inhibition in human cancer cells. Cancer Res., 53: 868-872, 1993.
24. Nesterova, M., and Cho-Chung, Y. S. A single-injection protein kinase A-directecl antisense treatment to inhibit tumor growth. Nat Med., 1: 528-533, 1995.
25. Tortora, G., Caputo, R., Pomatico, G., Pepe, S., Bianco, A. R., Agrawal, S., Mendelsohn, J., and Ciardiello, F. Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth. Clin. Cancer Res., 5: 875-881, 1999.
26. Zhang, R., Lu, Z., Zhao, H., Zhang, X., Diasio, R. B., Habus, I., Jiang, Z., Iyer, R. P., Yu, D., and Agrawal, S. In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats. Biochem. Pharmacol., 50: 545-556, 1995.
27. Green, S., and Weiss, G. R. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest. New Drugs, 10: 239-253, 1992.
28. Martin, R. R. Early clinical trials with GEM91, a systemic oligodeoxynucleotide. In: C. A. Stein and A. M. King (eds.), Applied Antisense Oligonucleotide Technology, pp. 387-393. New York: Wiley-Liss, 1998.
29. Glover, J. M., Leeds, J. M., Mant, T. G., Amin, D., Kisner, D. L., Zuckerman, J. E., Geary, R. S., Levin, A. A., and Shanahan, W. R., Jr. Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). J. Pharmacol. Exp. Ther., 282: 1173-1180, 1997.
30. Agrawal, S. Antisense oligonucleotides: towards clinical trials. Trends Biotechnol., 14: 376-387, 1996.